Registration open for 13th Annual Meeting of the Society of Hematologic Oncology
The Society of Hematologic Oncology (SOHO) has opened registration for its annual meeting; register before June 8, 2025, for early-bird rates. Event dates: September
Society Updates
Lymphoma
News
Early-phase trial shows promise for refractory CD30-positive lymphoma
A CD30/CD16A bispecific antibody, AFM13, “showed encouraging preliminary safety and efficacy
Lymphoma
Aggressive B-Cell Lymphomas
ELM-1 cohort study assesses odronextamab after CAR-T therapy for DLBCL
Odronextamab monotherapy resulted in a 48.3% overall response rate in patients with diffuse large B-cell lymphoma (DLBCL) who had progressed after chimeric antigen
News
Video Interviews
Dr. Kidson-Gerber discusses guidelines for pregnant patients with blood cancers
Giselle Kidson-Gerber, FRACP, FRCPA, a hematologist and clinical researcher at Prince of Wales Hospital and the Royal Hospital for Women, Sydney, discusses the
Cellular Therapy
Early-phase study shows promise of novel CAR-T talicabtagene autoleucel for B-cell malignancies
The novel chimeric antigen receptor (CAR) T-cell therapy talicabtagene autoleucel induced durable responses in an Indian population with relapsed or refractory B-cell malignancies,
News
Phase 3 trial recruiting for quizartinib plus chemotherapy in FLT3-ITD-negative AML
The phase 2 PETHEMA-QUIWI study of quizartinib plus chemotherapy showed significantly improved overall survival (OS) and served as the backbone for this new
Multiple Myeloma
News
ISAF approves equecabtagene autoleucel for relapsed or refractory multiple myeloma
The Pharmaceutical Administration Bureau of the Macao Special Administrative Region (ISAF) has approved equecabtagene autoleucel (FUCASO) for the treatment of adult patients with
Cellular Therapy
2025 EBMT Annual Meeting
Multiple Myeloma
News
CARTITUDE-4: Nearly 75% of patients alive 3 years after cilta-cel treatment for myeloma
Nearly three years after treatment with the chimeric antigen receptor T-cell therapy ciltacabtagene autoleucel (cilta-cel), the risk of death was reduced by 45%
Leukemia
News
Experts issue guidance on treating blood cancers during pregnancy
The incidence of hematologic malignancies presenting during pregnancy has increased, so Georgia Mills, MBBS (Hons), FRACP, FRCPA, of Northern Beaches Hospital in Sydney,
2025 EBMT Annual Meeting
Orca-T immunotherapy reduces GVHD over conventional allogeneic HSCT
Orca-T is an allogeneic stem cell and T-cell immunotherapy that leverages high-purity regulatory T cells to prevent GVHD.